Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

This study has been completed.
ChemGenex Pharmaceuticals
Information provided by (Responsible Party):
Teva Pharmaceutical Industries Identifier:
First received: April 17, 2007
Last updated: September 23, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2013
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: May 3, 2012